Skip to main content
XVIPF logo

Xvivo Perfusion AB (publ) (XVIPF) Stock Price & Analysis

Xvivo Perfusion AB (publ) (XVIPF) — price $19.00 (0.00%), as of the Nov 19, 2026 trading session; market cap $598M.

Educational signal · not a buy or sell recommendation · How to read this

$19.00 $0.00 (0.00%) Market Cap $598M

Xvivo Perfusion AB (publ) · XVIPF

Xvivo Perfusion AB (publ) is a medical technology company specializing in organ preservation and perfusion solutions for transplantation. With a focus on innovative products for ex-vivo lung perfusion, the company operates in a growing market driven by increasing demand for transplantable organs.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SYK · Stryker Corporation · 80 /100
  • TMO · Thermo Fisher Scientific Inc. · 70 /100
  • BDX · Becton, Dickinson and Company · 68 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$19.00
Change on the day0.00%
Market capitalisation$598M—
Price / earnings (trailing)47.92
Shares traded on the day592

Price & events

Other perspectives

Council score for Xvivo Perfusion AB (publ) (XVIPF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Debt/Equity Strong
ROE Neutral
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Xvivo Perfusion AB (publ) (XVIPF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Xvivo Perfusion AB (publ) (XVIPF) is the company analyzed here. It employs 207 people. The market values it at $598M.

3 · Financial strengths and risks

What are the financial strengths and risks for Xvivo Perfusion AB (publ) (XVIPF)?

Short answer

The distress and quality screens read Altman Z 12.17 · Piotroski F 6. Trailing ratios: ROE 5.9% · ROA 3.2% · current ratio 3.92.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held XVIPF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported XVIPF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Xvivo Perfusion AB (publ) (XVIPF)?

Read these with our analysis →

Xvivo Perfusion AB (publ) Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the XVIPF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is XVIPF a good stock to buy?

Stock Expert AI does not rate XVIPF buy, sell or hold. Xvivo Perfusion AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the XVIPF stock price today?

The last price recorded for Xvivo Perfusion AB (publ) (XVIPF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What revenue streams does Xvivo Perfusion AB (publ) have in healthcare?

Xvivo Perfusion AB (publ) generates revenue primarily through the sale of its innovative medical devices and solutions for organ preservation and perfusion. Key products include the XVIVO System, STEEN Solution, and various disposable products tailored for transplantation needs.

What are the key factors to evaluate for XVIPF?

Evaluate XVIPF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does XVIPF data refresh on this page?

XVIPF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven XVIPF's recent stock price performance?

Xvivo Perfusion AB (publ) (XVIPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings that address critical needs in organ transplantation. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider XVIPF overvalued or undervalued right now?

The trailing P/E of Xvivo Perfusion AB (publ) (XVIPF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research XVIPF before investing?

Before investing in Xvivo Perfusion AB (publ) (XVIPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 9 figures on this page — 6 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.